Australian PrescriberPub Date : 2022-08-01Epub Date: 2022-06-07DOI: 10.18773/austprescr.2022.043
{"title":"Trastuzumab deruxtecan for breast cancer.","authors":"","doi":"10.18773/austprescr.2022.043","DOIUrl":"https://doi.org/10.18773/austprescr.2022.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"146"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/99/austprescr-45-146.PMC9427624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Guidelines not for everyone.","authors":"Shyan Goh","doi":"10.18773/austprescr.2022.049","DOIUrl":"https://doi.org/10.18773/austprescr.2022.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"117"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/4d/austprescr-45-117.PMC9427622.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The anticholinergic burden: from research to practice.","authors":"Sarah N Hilmer, Danijela Gnjidic","doi":"10.18773/austprescr.2022.031","DOIUrl":"https://doi.org/10.18773/austprescr.2022.031","url":null,"abstract":"<p><p>Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"118-120"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/5e/austprescr-45-118.PMC9427617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Australian PrescriberPub Date : 2022-08-01Epub Date: 2022-06-23DOI: 10.18773/austprescr.2022.037
{"title":"Erratum: Hormonal contraception and mood disorders [Correction].","authors":"","doi":"10.18773/austprescr.2022.037","DOIUrl":"https://doi.org/10.18773/austprescr.2022.037","url":null,"abstract":"<p><p>[This corrects the article on p. 75 in vol. 45, PMID: 35755988.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"147"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/93/austprescr-45-147.PMC9427623.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Off-label drugs for obesity.","authors":"Andy Morgan, Liz Sturgiss","doi":"10.18773/austprescr.2022.046","DOIUrl":"https://doi.org/10.18773/austprescr.2022.046","url":null,"abstract":"The concluding statement ‘They [weight-loss drugs] are useful during the weight loss phase, but are essential in the maintenance phase’ is contentious but presented as fact. Despite these drugs being used for decades, there are still no trials reporting their benefit on end points, such as cardiovascular events and death. A Cochrane review of their longterm effects in people with hypertension found only one randomised trial reporting cardiovascular outcomes. This showed no differences in all-cause mortality or cardiovascular mortality or morbidity.2","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"114"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/6a/austprescr-45-114.PMC9427632.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sodium-glucose co-transporter 2 inhibitors beyond diabetes.","authors":"Dimity L Williams, Serena Rofail, John J Atherton","doi":"10.18773/austprescr.2022.036","DOIUrl":"https://doi.org/10.18773/austprescr.2022.036","url":null,"abstract":"<p><p>Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease. This led to further trials that included patients without diabetes. In studies of heart failure, SGLT2 inhibitors were beneficial in treating patients with a reduced left ventricular ejection fraction. A recent study has also reported benefits in patients with a preserved ejection fraction. In chronic kidney disease, SGLT2 inhibitors may reduce disease progression. However, a decline in the glomerular filtration rate may be seen at the start of treatment. As most experience with SGLT2 inhibitors is in diabetes, patients without diabetes need to be aware of why they are being prescribed these drugs. Some of the potential indications for SGLT2 inhibitors beyond diabetes are not yet approved by regulatory authorities.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"121-124"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/05/austprescr-45-121.PMC9427625.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
